Nexvet Biopharma plc 4
4 · Nexvet Biopharma plc · Filed Sep 7, 2016
Insider Transaction Report
Form 4
Lismore Damian T.
Chief Financial Officer
Transactions
- Exercise/Conversion
Restricted Share Units
2016-09-05+65,000→ 65,000 totalExercise: $0.13Exp: 2021-07-01→ Ordinary Shares (65,000 underlying)
Footnotes (1)
- [F1]16,250 of the Restricted Share Units shall vest and become convertible on each of 7/1/17, 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.